Valentin Kahl and Roman Zantl Among the Top 25 Healthcare Technology CEOs of Europe 2020

ibidi is pleased to announce that their CEOs, Dr. Valentin Kahl and Dr. Roman Zantl, have been recognized together in the ranking of the Top 25 Healthcare Technology CEOs of Europe for 2020.

Each year, the Healthcare Technology Report recognizes top-performing company leaders worldwide. This year, however, has provided a host of new challenges to the healthcare industry, and companies in this sector have had to adapt to shifting priorities within the market. The 2020 awardees successfully led their companies through these challenging times, and their expert leadership has guided the production of innovative solutions for complex problems across healthcare technology verticals.

ibidi GmbH was founded as a spin-off venture from the Technical University of Munich and the University of Munich’s Center of Nanoscience in 2001. Since then, the company has been developing and manufacturing cell-based assay technologies mainly for academia, but also for biotech and pharma enterprises across the globe. Cofounders Dr. Valentin Kahl and Dr. Roman Zantl continue to lead the company as CEO and President, respectively. They started ibidi directly after receiving their PhDs from the Technical University of Munich—Dr. Kahl in physics, and Dr. Zantl in biophysics. Nearly twenty years after its inception, they both continue to lead ibidi on a strong upward trajectory, helping researchers across biology, pharma, and medicine gain increasing, and more reliable, access to the nuances of cell function.

“We are very proud to receive this outstanding international award,” says Dr. Valentin Kahl, CEO at ibidi. “This positive feedback from industry professionals encourages us to continue the ibidi success story.”

The nominees were evaluated based on their breadth and depth of experience, consistently high organizational performance, contributions to the industry, and reputation among peers. Each of the CEOs recognized has had a profound impact on the companies they lead, including making strategic decisions to drive operational expansion, augmenting research capabilities, and launching new products and services.

About the Healthcare Technology Report thehealthcaretechnologyreport.com

The Healthcare Technology Report provides industry executives, professionals, and investors with important news and information on the healthcare technology industry. It publishes annual awards features, which recognize top performing CEOs, women leaders, and executives who have achieved notable success in the past year. Success is determined in large part through feedback from industry professionals.

Über die ibidi GmbH

ibidi GmbH, located in Gräfelfing near Munich, Germany, is a leading supplier of functional cell-based assays and products for cell microscopy. The ibidi range of products offers solutions for classic cell culturing, and also complex assays (e.g., angiogenesis, chemotaxis, and wound healing). Their products help facilitate an understanding of the development of various diseases and related therapies. ibidi’s customers are working in scientific institutions, industrial pharmacology, and biotechnology. Technology development at ibidi is supported by the BMBF (Bundesministerium für Bildung und Forschung). The products are sold to customers worldwide.

Firmenkontakt und Herausgeber der Meldung:

ibidi GmbH
Lochhamer Schlag 11
82166 Gräfelfing bei München
Telefon: +49 (89) 5204617-0
Telefax: +49 (89) 5204617-59
http://www.ibidi.de

Ansprechpartner:
Dr. Susanne Seifert
Marketing
Telefon: +49 89 520 46 17-0
Fax: +49 (89) 5204617-59
E-Mail: info@ibidi.de
Für die oben stehende Pressemitteilung ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.

counterpixel